Information updates

Updated ASCIA IVIg Infusion Guidelines

ASCIA Intravenous Immunoglobulin (IVIg) Infusion Guidelines provide standardised infusion rates for both 5% and 10% IVIg solutions, regardless of product. These have been developed to avoid confusion, as individual IVIg products recommend different weight-based rates of infusion.

ASCIA IVIg Infusion Guidelines have been updated in April 2023 and are available at 

The updates include:

  • Details about Privigen AU® (CSL Behring), which will replace Intragam® 10 when it is phased out in 2023.
  • Details about Flebogamma® 10% (Grifols), Gamunex® (Grifols), Kiovig® (Takeda) and Octagam® 10%  (Octapharm).
  • Addition of ‘A reduction in maximum infusion rate may be required if post infusion symptoms such as headache or myalgia occur’ to the guide to follow when adverse reactions occur.
  • Amendment of 3 ml/kg/hour to 6 ml/kg/hour under ‘Subsequent Infusions’.

The rates that are recommended in the ASCIA Guidelines are generally well tolerated and are for patients with immune deficiency on replacement IVIg therapy. Patients using IVIg for other conditions such as Kawasaki disease or immunomodulation should follow local protocols.

This news item was issued on 14 April 2023 by Jill Smith, CEO of the Australasian Society of Clinical Immunology and Allergy (ASCIA). ASCIA is the peak professional body for clinical immunology and allergy in Australia and New Zealand. 


Mod ASCIA Member
Donate to AIFA
go to NAC website

ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Quick Links


ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...

The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...

Disclaimer I Privacy

The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors | Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites. 

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.

Information Partner

Official Information Partner of Healthdirect Australia